GBI Magazine recently spoke to Dr Caroline Barelle, CEO & Founder of Elasmogen, to talk about her Start-Up journey and how the Deepbridge Life Sciences EIS Scheme influenced it. 

Elasmogen is a biopharmaceutical company located in the thriving biologics cluster in Aberdeen, Scotland. The Company is rapidly progressing a pipeline of next-generation soloMER™ products for the treatment solid-tumour cancers, systemic inflammatory diseases and inflammatory conditions of the gut. Discovering and developing soloMERs™ for the treatment of auto-immune mediated, inflammatory diseases. Utilising its unique soloMER™ platform, Elasmogen exploits the power of biologics as drugs but in small, simple, and stable formats that are amenable to site-specific delivery.

Being led by industry professionals with broad experience that covers both big Pharma and early-stage biotech. The Elasmogen team has a demonstrated track-record of delivering biologic drugs to the clinic and of securing company exits via trade-sale and IPO.

If you would like to watch the interview with Dr Caroline Barelle, click here. 

Click here to read the article. (By following either of these links you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites).